Peter Helt Jacobsen Haahr

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.

Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.

LEO Fondet provides support for research in the fields of medicine, chemistry, and pharmacy. The company was founded on August 20, 1984 and is headquartered in Ballerup, Denmark.

Leo Pharma, Inc. is engaged in the development, manufacture, and marketing of pharmaceutical drugs. Its products are used for dermatologic and thrombotic patients. The company was founded in 1908 and is headquartered in Parsippany, NJ.

Part of Sonion A/S, Sonion Holdco A/S is an investment holding Danish company. The company is based in Hellerup, Denmark.

Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets.

LEO Holding A/S invests in company with interest in medical dermatology. The company was founded on November 29, 2017 and is headquartered in Copenhagen, Denmark.